ArticleScientific reports2026
Epidemiological and pathogen characteristics of symptomatic male reproductive tract infections in Hunan province: retrospective study.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Male reproductive tract infections (MRTIs) are associated with serious clinical complications; however, their epidemiological characteristics remain insufficiently defined due to limitations in conventional diagnostic methods. This study utilized targeted next-generation sequencing (tNGS) to characterize the pathogen spectrum of MRTIs I n Hunan Province, China. Urethral swab specimens were collected from 594 male patients between February 2024 and January 2025. A tNGS panel targeting 61 pathogens was applied for pathogen detection. Statistical analyses were conducted using SPSS version 25.0. Of the 594 male reproductive tract swab samples analyzed, 484 (81.5%) were positive for at least one pathogen. Among the reported positive male samples, the highest positivity rate was observed in the 15-19-year age group (92.7%), followed by a gradual decline with age and a subsequent increase to 59.8% in individuals aged 40-49 years. The most prevalent bacterial pathogens were Ureaplasma parvum (29.5%), Ureaplasma urealyticum (23.3%), and Streptococcus agalactiae (23.3%). Subtype analysis of Ureaplasma parvum identified Ureaplasma parvum serovar 6 as the predominant subtype (11.4%), whereas Ureaplasma parvum serovar 14 was the least prevalent (0.6%). Other frequently detected pathogens included Candida albicans (7.2%) and Herpes simplex virus type 2 (3.3%). Among sexually transmitted pathogens, positivity rates were 5.2% for Neisseria gonorrhoeae and 0.8% for Treponema pallidum. High-risk Human papillomavirus infections were mainly attributable to Human papillomavirus 52 (19.2%) and Human papillomavirus 58 (8.7%). Co-infections were identified in 329 cases (68.0%), most commonly involving Streptococcus agalactiae (29.5%), Ureaplasma urealyticum (27.1%), Mycoplasma hominis (15.8%), and Human papillomavirus 52 (24.9%) or Human papillomavirus 58 (12.5%). Among HPV52-positive cases (n = 82), multi-subtype HPV co-infections most frequently involved HPV58 (25.6%), Human papillomavirus 53 (17.1%), and Human papillomavirus 51 (11.0%). In addition, bacterial co-infections in Human papillomavirus 53-positive samples were commonly associated with Ureaplasma urealyticum (23.2%), Streptococcus agalactiae (17.1%), and Ureaplasma parvum serovar 6 (12.2%). The tNGS-based analysis demonstrates a high burden of Human papillomavirus and Ureaplasma infections among men in Hunan Province, accompanied by complex co-infection patterns. The observed age-specific distribution of pathogens underscores the need for tailored prevention and control strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.